Introduction
Cystic fibrosis (CF), the most common genetic disorder in Caucasian populations, is caused by recessive mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (Cftr). 1 CFTR is an ATP-binding cassette (ABC) transporter that plays a critical role in salt transport and fluid movement by controlling chloride ion transport across epithelia. 2 Dysfunction of CFTR leads to disease in various organs including the respiratory and digestive tracts. However, the complications in the lung caused by abnormal airway secretions, chronic infection and inflammation pose the most serious threat to CF patients. 3 Currently, how the loss of CFTR function causes the clinical manifestations and pathological features of CF lung disease is not fully understood, so treatment is focused on management of respiratory infection and inflammation in the lung. 4 CF is considered one of the diseases that could be treated by gene therapy because it is a single gene disorder and the vector can be delivered directly to the lung through the airway. Moreover, restoration of normal Cftr mRNA to 5-10% could rescue the CF phenotype, 5, 6 although a recent review proposed that a higher level of expression may be required at the protein level. 7 In the last decade, adenovirus, adeno-associated virus (AAV) and nonviral vectors were developed and used in CF gene therapy clinical trials. 8 Gene therapy vectors are mostly studied in cultured cells, rodents and other animal models to verify their efficacy before clinical trials. However, an appropriate animal model to study CFTR functional correction in lung has not been achieved because Cftr knockout mice do not show the pulmonary pathologic features observed in human CF lung. 9 Although the Cftr knockout mouse models have been utilized to evaluate the therapeutic potential of CF gene therapy, [10] [11] [12] the lack of pathophysiology in the Cftr knockout mouse lung limits the interpretation of experimental results from CF mouse models. Therefore, an alternative model using a native human tissue is critically needed to assess the efficacy of CF gene therapy.
The eccrine sweat gland (referred to as 'sweat gland' below) is one of the organs affected by CF. The sweat gland is one of the smallest organs in the human body, uniquely developed in humans to control body temperature by evaporation. It has a simple tubular structure with only 2-3 layers of cells. Isotonic primary sweat is produced in the lower part of the sweat gland called the secretory coil, and, as the primary sweat moves to the skin surface through the sweat duct, electrolytes are reabsorbed by the epithelial cells from the apical membrane. CFTR plays an important role in sweat secretion and salt reabsorption in sweat glands, 13 and its dysfunction in CF patients results in salty sweat. The abnormal sweat composition in CF patients can be detected by a 'sweat test', a common diagnostic method used in CF clinics. Sweat glands do not manifest the anatomical alterations or pathology observed in other organs affected in the disease, and have been used as a model to study CFTR function and electrolyte transport pathophysiology. 14, 15 There are a number of advantages in using human sweat glands as a model to study CF. They are relatively easy to access from a skin punch biopsy, and the function of CFTR can be measured electrophysiologically in the apical membrane of the sweat duct ex vivo. 16 With these advantages, sweat glands could be a useful model to assess efficacy of CF gene therapy. Delivery and expression of normal Cftr to CF sweat glands is expected to restore the normal chloride transport function. Thus, it should be possible to evaluate the effectiveness of gene transfer and expression by the secretory response, biochemical analyses of the sweat, or electrophysiological properties according to well-established methods. 16 Furthermore, using sweat glands in studying CF gene therapy has significant implications for CF clinical trials. It is inherently safer and more practical to administer gene therapy vectors to a small punch biopsy or to a small region of skin, rather than to CF affected organs such as pancreas or lung. However, whether genes can be effectively delivered to human sweat glands remains to be shown. Although sweat glands may provide an important model to study the effect of CF gene therapy in human native tissues, differences in morphology and physiology exist between the sweat gland and the lung.
As a first step to explore the possibility of using sweat glands as a model for CF gene therapy, we investigated effective gene delivery methods using normal human sweat glands. We showed that transgenes can be efficiently delivered to the sweat gland cells by adenoviral gene therapy vectors. Furthermore, Cftr was delivered to, and expressed by, the target cells in the lumen of sweat glands using a helper-dependent adenovirus (HD-Ad) vector containing an epithelial cell-specific promoter. We also found that the basement membrane is an important barrier to adenoviral vector transduction.
Results

Transduction of human sweat glands in skin organ culture
Considering the small size of sweat glands and their ubiquitous distribution in human skin, we first attempted to transduce sweat glands embedded in the dermis of full-thickness skin organ culture. A small block of excised full-thickness skin (1 Â 1 cm) was maintained either at the air-liquid interface or submerged in culture medium, and exposed to a HD-Ad vector expressing b-galactosidase (HDD28E4LacZ) 17 by topical application or intradermal injection (air-liquid interface culture), or by incubation in virus-containing media (submersion culture). After 2 days of exposure to the vector, the skin tissue was assayed for b-galactosidase activity determined by reaction with X-gal. The transduction efficiency was very low and only a few cells in a few sweat glands stained with X-gal (Supplementary data, Figure  8 ). Those few transduced sweat glands were observed only in the intradermally injected or submersion organ cultures. No sweat gland transduction was observed by topical application of virus to skin in air-liquid interface culture.
Most transduced sweat glands were found at sites where they had been directly exposed to virus. For example, transduced sweat glands were found at the immediate site of the injection or at the excised periphery of the skin tissue in the submerged culture. This observation indicated that the adenovirus vector has limited ability to penetrate and transduce skin tissue in the organ culture. In order to increase the number of exposed sweat glands from the dermis, we treated the skin tissue with collagenase. Although collagenase partially digested the collagen-rich dermal matrix, it left the tissue sticky and did not noticeably increase the transduction efficiency. Nonetheless, we found that a few sweat glands at the periphery of the tissue, which were completely freed from the dermal matrix by the collagenase treatment, were transduced by the adenoviral vector (Figure 1 ). These results using skin organ culture suggested that the epidermis and dermal matrix are significant barriers to adenoviral vectors.
Gene delivery to isolated sweat glands
In an attempt to circumvent the barriers in skin tissue, we isolated sweat glands from the dermis by mechanically mincing the skin. 18 The isolated sweat glands were then incubated with HD-Ad vectors added to the media. Inoculating HDD28E4LacZ 17 (5 Â 10 10 viral particles) into 100 ml media containing isolated sweat glands appeared to increase the transduction and expression of the transgene in the sweat glands, highlighted by the large area of X-gal staining (Figure 2a) . However, when the histologic sections were examined most of the lacZ positive cells were found at the outer layer of the transduced sweat glands (Figure 2b ). In fact, most of the X-gal staining was in the remnant interstitial tissue, indicating that the HD-Ad did not penetrate to the inner layer of cells of the sweat gland when applied from the basal side. This limitation is a problem for using sweat gland as a CF gene therapy model because CFTR must be expressed and function at the luminal membrane.
19,20
Enhancement of gene delivery to isolated sweat glands
Since sweat gland tubules are only 2-3 cell layers thick, we suspected that the poor penetration of adenoviral vector was due to some of the remnant dermal component surrounding the sweat glands. We then treated the isolated sweat glands with collagenase (0.1 U/ml) and dispase (50 U/ml) overnight at 41C, before inoculating with the HD-Ad vector (the unit definition of the enzymes are defined by the manufacturers and do not correlate). These treatments not only dramatically increased the overall transduction efficiency but also resulted in transgene expression from the cells in the lumen (Figure 3a and c). Transduction efficiency was Gene delivery to human sweat glands H Lee et al correlated with the concentration of the proteases used. The relationship between the degree of enzymatic digestion and the transduction efficiency was further confirmed in other experiments, where the sweat glands were treated with dispase for various lengths of time as well as at different temperatures (Supplementary data, Figure 9 ).
Even though both collagenase and dispase significantly enhanced transduction efficiency at the higher concentrations, they showed different effects on gene delivery at lower concentrations. When sweat glands were treated with collagenase at 0.004 U/ml, the transduction was limited to the outer cell layer of the glands (Figure 3b ). On the other hand, the dispase treatment with the same factor of dilution (2 U/ml) resulted in fewer transduced glands, but the adenoviral vector delivered the transgene to the cells in the lumen of those glands ( Figure 3d ). These results suggested that pretreatment with dispase might be a more effective and specific method to improve gene delivery to the lumen of the sweat glands.
Basement membrane is the major barrier to adenoviral vector delivery
To further analyze how the dispase treatment increased transduction efficiency of sweat glands, we examined the integrity of the basement membrane after dispase treatment by immunostaining for type IV collagen. Type IV collagen is the most abundant constituent of basement membranes and assembles a sheet-like network with laminin to form the scaffold for the basement membrane. 21 When compared to intact sweat glands ( Figure  4a ), treatment with 50 U/ml dispase overnight at 41C significantly reduced type IV collagen in the basement membrane (Figure 4b ). Digestion for 8 h at 371C eliminated most of the type IV collagen at the basement membrane (Figure 4c ). From these results we conclude that the basement membrane is one of the major barriers to gene delivery to sweat glands using adenoviral vectors.
Cftr gene delivery to sweat glands with HD-Ad-K18CFTR
Our laboratory has developed HD-Ad vectors with control elements from the human cytokeratin 18 gene Gene delivery to human sweat glands H Lee et al (KRT18 or K18) for CF gene therapy. 10, 22 These vectors may be well suited for CF gene therapy because the K18 promoter can drive cell-specific expression in a pattern similar to that of Cftr.
23 K18 has been shown to be expressed in epithelial cells of various organs including sweat glands, 24 ,25 and we confirmed its expression in Figure 3 Enhanced transduction of sweat glands by enzyme pretreatment. The sweat glands were isolated from human skin tissue and treated with (a) collagenase, 0.1 U/ml; (b) collagenase, 0.004 U/ml; (c) dispase, 50 U/ml; or (d) dispase, 2 U/ml, prior to HDD28E4LacZ exposure. After overnight incubation at 41C in enzymes containing KGM media, sweat glands were transduced with HDD28E4LacZ. The unit definitions of the two enzymes are defined by the manufacturers and do not correlate (gross view magnification Â 90, histology magnification Â 200).
Gene delivery to human sweat glands H Lee et al human sweat glands by immunostaining (Supplementary data, Figure 10 ). We tested whether the K18 control elements could drive an expression pattern similar to that of native Cftr in sweat glands. Isolated sweat glands treated with dispase were exposed to HD-Ad-K18LacZ vector, which contained the b-galactosidase gene with a nuclear localization signal under the control of the K18 promoter. 22 As shown in Figure 5 transgene expression by HDAd-K18LacZ in sweat glands was distinctive from that of the human cytomegalovirus (CMV) promoter-driven vector HDD28E4LacZ (Figure 3a and c) . In general, the expression level was moderate compared to that achieved by HDD28E4LacZ, and showed a punctate transduction pattern (Figure 5a ). The histologic examination of HD-Ad-K18LacZ transduced sweat glands showed cell type-specific expression of the transgene (Figure 5b ). Unlike sweat glands transduced with HDD28E4LacZ, where all of the cells expressed the transgene, HD-Ad-K18LacZ induced lacZ expression specifically in the luminal cells. The condition of histologic sections of isolated sweat glands after dispase treatment and ex vivo culture prevented clear morpholo- Figure 5 Transduction of sweat glands by HD-Ad-K18LacZ. Isolated sweat glands pretreated with dispase were transduced by HD-AdK18LacZ. The lacZ expression in the transduced sweat glands was detected by X-gal staining (a, original magnification Â 90) and analyzed by histologic section (b, original magnification Â 200). In addition, the X-gal stained tissue sections were subjected to immunostaining with anti-cytokeratin 18 antibody to identify epithelial cells (c, original magnification Â 1000). Since the lacZ transgene in HD-Ad-K18LacZ contains a nuclear localization signal, X-gal staining (blue) was observed in the nuclei, whereas K18 was detected (brown) in the cytoplasm. Figure 4 Digestion of the basement membrane by dispase. Sweat glands were isolated and treated with (a) no enzyme, (b) dispase overnight at 41C, or (c) dispase for 8 h at 371C. Immunohistochemistry was carried out with frozen sections of the sweat glands using anti-type IV collagen. Type IV collagen was detected by DAB (brown) staining against methyl-green counter staining (green) (original magnification Â 100).
Gene delivery to human sweat glands H Lee et al gical identification of the cell types on sections. However, the epithelial cell-specific expression of the transgene was confirmed by double staining to detect K18 (by immunostaining) in the cytoplasm and LacZ (by X-gal staining) in the nucleus (Figure 5c ). The expression of lacZ transgene in luminal cells in this study was similar to the Cftr expression pattern detected in normal human sweat glands by immunohistochemistry in other studies. 19, 26 These results show that the HD-Ad vector with K18 control elements can drive an epithelial cell specific transgene expression in sweat glands.
Finally, we transduced sweat glands with HD-Ad-K18CFTR, our HD-Ad containing the human Cftr gene tagged with a VSV-G epitope under control of the K18 promoter. 10 Cftr expression was detected by RT-PCR using transgene-specific primers designed across K18 intron 1, which allowed us to distinguish the PCR product of the transgene Cftr mRNA from that of the endogenous Cftr mRNA or the vector DNA ( Figure 6 ). Furthermore, we confirmed Cftr gene expression in the epithelial cells of the lumen by immunostaining the sweat gland sections with anti-VSV-G antibody 3 days after transduction (Figure 7b ). CFTR-VSV-G was detected in the perinuclear region and at the plasma membrane of transduced cells in the sweat glands (Figure 7c) , consistent with our immunohistochemistry results for the endogenous CFTR of the human sweat gland (Supplementary data, Figure 11 ) as well as previous reports of the intracellular localization of CFTR. 27 
Discussion
This study investigated gene delivery to human sweat glands to explore the possibility of using sweat glands as a model for CF gene therapy. Prior to this study there have been no reports of gene delivery directed to human sweat glands. One study reported partial transduction of sweat glands when an AAV vector was intradermally injected into pig skin. 28 Using various methods we attempted to deliver genes using an HD-Ad vector to human skin in organ culture. We found that gene delivery to sweat glands in intact human skin was very inefficient ex vivo. In general, topical gene delivery has been considered to be difficult for cutaneous gene therapy. 29 A number of gene delivery studies with adenoviral vectors showed that it is possible to achieve a significant transduction of mouse epidermis in vivo, and skin appendages such as hair follicles and sebaceous glands can be transduced in mouse skin. [30] [31] [32] The discrepancy between the transduction we observed with our human skin organ culture and what others have observed in vivo may reflect inherent differences between eccrine sweat glands and other skin appendages, mouse versus human species differences, and/or differences between skin in organ culture versus skin in vivo.
Our observations indicated that the basement membrane is a critical barrier to the delivery of adenoviral 5' UTR Figure 6 Expression of Cftr by sweat glands transduced with HD-Ad-K18-CFTR. A total of 50 sweat glands were treated with dispase overnight and transduced with HD-Ad-K18-CFTR for 2 days. The total RNA was isolated and cDNA was generated using a common reverse primer (black arrow head). Forward primers designed specifically at the K18 exon 1 (gray arrow head) or 5 0 UTR of Cftr (unfilled arrow head) were used in PCR (35 cycles Gene delivery to human sweat glands H Lee et al vectors from the basal side of sweat glands. The basement membrane has been suggested as a physical barrier to herpes simplex virus (HSV) vectors, 33 and Weeks et al 34 showed that the intradermal injection of HSV below the epidermal basement membrane did not cause pathogenesis. In Duchenne muscular dystrophy gene therapy, the ineffectiveness of viral vectors to transduce mature muscle has been a major impediment. 35 Huard et al 33 reported that the more mature basement membrane of the muscle fiber in adult mice, compared to newborn mice, acted as barrier for HSV vector transduction. Van Deutekom et al 35 also showed that treating myofibers with streptokinase, a fibrinolytic drug, enhanced transduction efficiency of the HSV vector in mature skeletal muscle, suggesting basement membrane and surrounding extracellular matrix as a physical barrier. Interestingly, Pruchnic et al 36 reported that AAV could transduce mature as well as immature muscle fibers, and proposed that the small size of AAV, compared to other viral vectors, might have contributed its ability to penetrate the basement membrane.
We were able to significantly enhance adenoviral gene delivery to sweat glands by dispase pretreatment. Saito et al 37 used collagenase to enhance the gene transfer to hair follicle from mouse and suggested that partial digestion of the dermis might have increased the transduction efficiency. We also achieved comparable transduction efficiencies with sufficient collagenase treatment instead of dispase. However, dispase treatments were more effective than the collagenase at higher dilutions ( Figure  3b and d) . Commercially available collagenase and dispase are extracts from bacterial cultures and exhibit various proteinase activities, but dispase is considered an effective reagent for digestion of basement components such as fibronectin and type IV collagen. 38 Our immunostaining for type IV collagen demonstrated that degradation of the basement membrane was correlated with enhanced transduction efficiency. Although we used dispase treatment to enhance gene delivery from the basal side of the sweat gland in our ex vivo study, an alternative method could be used to deliver genes to sweat glands without the enzyme pretreatment, to preserve tissue integrity. One of the plausible methodologies is microperfusion. Microperfusion of gland tubules has been used to study electrophysiology and CFTR functions in sweat ducts. 14, 15 This technique would allow delivery of the vector directly to the lumen of sweat glands instead of from the basal side, without enzyme pretreatment. Once the vector is delivered to the sweat tubule, the chloride conductance could be quantitatively measured to evaluate CFTR function in the sweat gland. 16 In this study, we have demonstrated that it is possible to deliver Cftr to sweat glands using an HD-Ad, and to express CFTR in the epithelial cells in the lumen. Our results provide the basis to study the functional efficacy of CF gene therapy using human sweat glands, and we propose that sweat glands could be used as an alternative model. Delivery of Cftr to sweat glands from a CF patient should restore normal CFTR function of b-adrenergically stimulated secretion, lower sweat salt concentrations, and enhance Cl À conductance in sweat ducts. These changes can be quantitatively evaluated by biochemical and electrophysiological methods. [14] [15] [16] Future studies should be directed toward detecting these changes in sweat secretion function using sweat glands from CF patients.
The study of functional efficacy is an important step toward a successful CF gene therapy. In addition to molecular end points, such as mRNA and protein expression, clinical trials often relied on nasal electrical potential difference to detect correction of the chloride transport function. 8 However, measuring nasal potential difference is known to be a variable technique 39 and there have been conflicting results questioning the sensitivity of the method for measuring CFTR function. 40, 41 Although the nasal epithelium is more closely related to the lung epithelium in its electrophysiology, the sweat gland could provide an alternative model to assess the efficacy of the gene therapy vector in an organ without disease pathology. One difficulty would be the currently less widespread use of sweat gland electophysiology techniques [14] [15] [16] compared to nasal potential difference measurement.
In addition to quantitative assays for the functional evaluation of gene therapy, the sweat gland model could provide advantages in clinical trials. Gene delivery to sweat glands from the skin surface or to sweat glands isolated from a punch biopsy would be more convenient than delivery to the nasal cavity or the lung. More importantly, ex vivo transduction of sweat glands, or transduction of sweat glands in a small region of skin, would not be a major safety and ethics concern compared to applying viral vectors to pathologically compromised organs such as the CF lung. The sweat gland model can also provide a way to predict compliance to the gene therapy for each individual patient, by testing his own sweat glands prior to treatment of the CF affected organ. With these potential clinical implications, the sweat gland could be considered as an alternative model to study efficacy of CF gene therapy in humans.
Materials and methods
Helper-dependent adenoviral vectors
Construction of the HDD28E4LacZ, HD-Ad-K18LacZ and HD-Ad-K18CFTR HD-Ad vectors has been described previously. HDD28E4LacZ contains bacterial lacZ under control of the CMV immediate-early promoter. 17 HD-Ad-K18LacZ and HD-Ad-K18CFTR have 2.5 kb of genomic sequence upstream from the cytokeratin 18 (K18) gene containing the promoter plus first intron of K18 followed by a translation enhancer. 10, 22 HD-AdK18LacZ contains a nuclear localization signal from SV40 antigen. 22 HD-Ad-K18CFTR has the vesticular stomatitis virus G glycoprotein (VSV-G) epitope tag at the Cterminus of CFTR. 10 The HD-Ads were prepared as previously described. 17 The final concentration of virus was 5-8 Â 10 12 viral particles/ml.
Preparation of full thickness skin and gene delivery using skin organ culture
Human skin tissue was obtained from abdominal pannus excised from otherwise healthy subjects undergoing dermolipectomy. A clinical protocol (HSC protocol # 001960042) was approved for ex vivo experiments on the skin tissue. The hypodermal fat was removed from the skin and the full-thickness skin was briefly washed
Gene delivery to human sweat glands H Lee et al with PBS. For skin organ culture study the full-thickness skin was cut into 1 Â 1 cm pieces and either submerged in media or placed on the Transwell culture system (Costar, Corning, NY, USA), such that the dermis contacted the medium while the epidermis remained exposed to the air. RPMI 1640 containing 10% FBS was used as the culture media. The skin was transduced by topical application or injection of adenovirus, or by addition of adenovirus to the submersion culture medium. For topical application, 10 ml of virus solution, containing 2.5 Â 10 10 virus particles, was carefully laid on the epidermis in the center of the skin sample. For injection, the same number of virus particles (in 5 ml) was intradermally injected using a 30G needle. For submersion culture, the same number of virus particles was added to 1 ml media, which contained the skin sample. The tissue was incubated for 2 days in a 5% CO 2 incubator at 371C and then stained with X-gal. In order to digest the dermal matrix, full-thickness skin was placed in 2 mg/ml of collagenase (274 U/mg) (Worthington Biochemicals, Lakewood, NJ, USA) in aMEM with 1% FBS for 2 h at 371C.
Isolation of sweat glands and transduction
Sweat glands were isolated under a dissection microscope after mincing 1 Â 0.5 cm full-thickness skin with fine surgical scissors. 18 The isolated sweat glands were maintained in KGM media (Clonetics, Walkersville, MD, USA) during isolation and the transduction experiment. The sweat glands were digested in 100 ml of KGM containing 10% dispase (5000 U/ml) (Collaborative Research, Bedford, MA, USA) overnight at 41C, unless specified otherwise. Alternatively, collagenase H (0.2 U/ml) (Roche, Mannheim, Germany), diluted in KGM, was used to compare transduction efficiencies. The unit definitions of dispase and collagenase were defined by the manufacturers and do not correlate. Five to ten isolated sweat glands in each well of a 96-well dish were washed twice in PBS and cultured in 100 ml of KGM. The HD-Ad (2.5-5 Â 10 10 particles) was added directly to the media and the culture maintained for 2 days, except when specified otherwise.
X-gal staining
Sweat glands transduced with HD-Ad vectors containing lacZ were assayed for b-galactosidase activity by reaction with X-gal. The sweat glands were briefly washed in PBS and fixed in fixative solution (1% formaldehyde, 0.1% glutaraldehyde, 2 mM MgCl 2 , 5 mM EGTA in 0.1 M sodium phosphate buffer, pH 7.8) by incubating for 30 min at 41C with gentle mixing. After washing twice for 15 min in washing solution (2 mM MgCl 2 , 0.02% NP-40, 0.01% deoxycholate in 0.1 M sodium phosphate buffer, pH 7.8) at 41C, the tissue was stained with X-gal solution (wash solution plus 5 mM K 4 Fe(CN) 6 :3H 2 O, 5 mM K 3 Fe(CN) 6 , 1 mg/ml 5-bromo-4-choloro-3-indolyl b-D-galactopyranoside) for 2 h at 371C. Samples were then rinsed in 70% ethanol, and further fixed in 4% paraformaldehyde for 1 h at 41C. We used same methods for skin tissue but allowed longer incubation times. The stained tissue samples were sectioned after embedded in paraffin or OCT (Tissue-Tek, Torrance, CA, USA) and counter stained with neutral red.
Immunohistochemisty
The transduced sweat glands were treated in fixative solution (as above) for 30 min at 41C and embedded in OCT for cryosection, or in paraffin after a series of short dehydration steps in 70% (20 min), 90% (20 min), 100% ethanol (2 Â 20 min), and xylene (2 Â 30 min). Both frozen and paraffin sections were cut 5 mm in thickness and paraffin sections were deparaffinized prior to immunostaining. Tissue sections were rehydrated in PBS, treated with 0.2% Triton X-100 in PBS for 4 min, quenched with 0.3% H 2 O 2 for 10 min, and blocked with blocking buffer (2% BSA, 5% goat serum) for 30 min. Then, monoclonal antibody against VSV-G (1:2000 dilution, Boehringer Mannheim, Indianapolis, IN, USA) or human type IV collagen (1:2500 dilution, Chemicon, Boronia, Australia) diluted in blocking buffer was applied to the section. The primary antibodies were detected using the Vectastain Kit and DAB Substrate Kit for Peroxidase (Vector Laboratories, Burlingame, CA, USA), according to the manufacturer's recommendations. Finally, the sections were counter stained with either neutral red or methyl green. For K18/LacZ double staining, the X-gal stained sweat glands were embedded in paraffin and subjected to immunostaining with anti-cytokeratin 18 antibody (1:20 dilution, RDI, Flanders, NJ, USA).
RT-PCR
A total of 50 isolated sweat glands were transduced with 1.24 Â 10 11 particles of HD-Ad-K18-CFTR in 100 ml of KGM for 2 days as described above. The total RNA was isolated in 500 ml of TRIzol (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's recommendations following tissue disruption by a cycle of freezing and thawing and vigorous pippetting. cDNA was generated using a common reverse primer (5 0 -ccgaagggcattaatgagtttagg-3 0 ) in the coding region of Cftr, and the forward primers designed specifically at the K18 exon 1 (5 0 -GTCCGCAAAGCCTGAGTCCTGTCC-3 0 ) or 5 0 UTR of Cftr (5 0 -ATCACAGCAGGTCAGAGAAAAAG-3 0 ) were used in PCR to detect the transgene or endogenous Cftr expression, respectively. The expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was also detected by RT-PCR using a reverse primer (5 0 -GATG ATGACCCGTTTGGCTCC-3 0 ) and a forward primer (5 0 -CTGGTAAAGTGGATATTGTTGCC-3 0 ). The PCR reactions were performed for 35 cycles, except for GAPDH, whose PCR reaction was performed for 25 cycles.
